Abstract: Disclosed are rationally-designed, non-naturally-occurring meganucleases in which a pair of enzyme subunits having specificity for different recognition sequence half-sites are joined into a single polypeptide to form a functional heterodimer with a non-palindromic recognition sequence. The invention also relates to methods of producing such meganucleases, and methods of producing recombinant nucleic acids and organisms using such meganucleases.
Abstract: In some aspects, the invention relates to selectively permeable cell culture vessel storage containers and their methods of use. In some embodiments, the containers comprise a gas-permeable membrane that is selectively impermeable to water vapor.
Abstract: The present disclosure is directed to compounds having a structure according to Formula I, and compositions containing those compounds. Methods of using the compounds for the treatment of diseases, disorders, or conditions are also described.
Abstract: A method and apparatus for measuring cells and cell confluence includes an imager for imaging a z-stack of bright field images and a processor for selecting a best focus bright field image at a z position of f microns in the z-stack of images. In the manner described herein, the processor selects a bright image n microns lower in the z-stack than the best focus bright field image and a dark image m microns higher in the stack than the best focus bright field image. The processor applies edge detection to the dark image to obtain an edge image and subtracts the edge image from the dark image and the processor applies an adaptive threshold to the bright image to create a mask and uses the adaptive thresholded image as seeds to evaluate the edge image to find cell candidates.
Type:
Application
Filed:
January 19, 2023
Publication date:
May 8, 2025
Applicant:
Thrive Bioscience, Inc.
Inventors:
Alan BLANCHARD, Kenneth CHAPMAN, Frank EVANS
Abstract: The present disclosure relates to circular, non-viral DNA vectors, compositions including one or more of the disclosed vectors, and methods for delivering and/or expressing one or more therapeutic genes (e.g., proteins) in mammals, e.g., human patients. In some embodiments, the present disclosure is directed to circular, non-viral DNA vectors, such as circular non-viral DNA vectors including at least two inverted repeat sequences, where the at least two inverted repeat sequences are separated by a non-repeated nucleotide sequence which is not part of the at least two inverted repeat sequences. In some embodiments, the disclosed circular, non-viral DNA vectors do not include a “DD element.” In some embodiments, the disclosed circular, non-viral DNA vectors do not include a “DD element,” but include at least a portion of a bacterial origin of replication.
Abstract: The present disclosure relates to circular, non-viral DNA vectors, compositions including one or more of the disclosed vectors, and methods for delivering and/or expressing one or more therapeutic genes (e.g., proteins) in mammals, e.g., human patients. In some embodiments, the present disclosure is directed to circular, non-viral DNA vectors, such as circular non-viral DNA vectors including at least two inverted repeat sequences, where the at least two inverted repeat sequences are separated by a non-repeated nucleotide sequence which is not part of the at least two inverted repeat sequences. In some embodiments, the disclosed circular, non-viral DNA vectors do not include a “DD element.” In some embodiments, the disclosed circular, non-viral DNA vectors do not include a “DD element,” but include at least a portion of a bacterial origin of replication.
Abstract: Disclosed are compounds and compositions for the activation or induction of expression of a pattern recognition receptor (e.g., STING, RIG-I, MDA5), and methods of use thereof.
Type:
Grant
Filed:
July 8, 2019
Date of Patent:
May 6, 2025
Assignee:
Sperovie Biosciences, Inc.
Inventors:
Radhakrishnan P. Iyer, Geeta Meher, Sreerupa Challa, Shenghua Zhou
Abstract: Provided herein is the identification of the causal gene KR associated with THCV, THCVA, CBDV, CBDVA, CBGV, CBGVA, CBCV, or CBCVA production in Cannabis plants. Also included are isolated cells, nucleic acids, transgenic Cannabis plants; methods of editing, and methods of using marker assisted selection to select and establish plant lines having modified THCV, THCVA, CBDV, CBDVA, CBGV, CBGVA, CBCV, or CBCVA activity.
Abstract: The invention provides non-hormonal vitamin D conjugated to apelin proteins that result in increased absorption, bioavailability or circulating half-life when compared to non-conjugated forms. In some embodiments, the vitamin D targeting groups are coupled to the apelin proteins via the third carbon on the vitamin D backbone.
Type:
Application
Filed:
July 23, 2024
Publication date:
May 1, 2025
Applicant:
Extend Biosciences, Inc.
Inventors:
Tarik Soliman, Laura M. Hales, Daniel B. Hall, Christopher So, Howard P. Sard, Vishnumurthy Hegde
Abstract: The present disclosure provides compounds and pharmaceutically acceptable salt thereof, and methods of using the same. The compounds and methods have a range of utilities as therapeutics, diagnostics, and research tools. In particular, the subject compositions and methods are useful for reducing signaling output of oncogenic proteins.
Abstract: A compact sorting flow cytometer system includes a fluidics system having a flow cell and a deflection chamber in communication with the flow cell and a droplet deposition unit (DDU) system in communication with the deflection chamber. The defection chamber receives drops in a stream of a sample biological fluid with one or more biological cells or particles and selectively deflect the drops in the stream. The DDU system is in communication with the deflection chamber to receive the selectively deflected drops into one or more containers. The DDU system includes a case forming a portion of a containment chamber. When closed, one or more doors seal and close off the containment chamber from an external environment. Air can be evacuated from the containment chamber by one or more fans in one or more tunnels. Air can be conditioned by a thermoelectric cooling array between the containment chamber and an air conditioning chamber that is moved by one or more fans.
Type:
Grant
Filed:
February 4, 2022
Date of Patent:
April 29, 2025
Assignee:
Cytek Biosciences, Inc.
Inventors:
Glen Krueger, David Vrane, Kuncheng Wang, Qiuta Gu
Abstract: The application relates to the field of oncology, cancer immunotherapy, molecular biology and recombinant nucleic acid technology. In particular, the invention relates to genetically-modified eukaryotic cells comprising modulated TGF Beta signaling. The application further relates to the use of such genetically-modified eukaryotic cells for treating a disease, including cancer, in a subject.
Abstract: Provided herein is the identification of genetic markers associated with modified cannabinoids relating to levels or ratios of one or more of tetrahydrocannabinol (THC), cannabidiol (CBD), cannabigerol (CBG), tetrahydrocannabivarin (THCV), cannabidivarin (CBDV), cannabichromene (CBC), or cannabigerovarin (CBGV). The markers are useful for breeding plants having modified cannabinoids by obtaining nucleic acids, detecting one or more markers that indicate modified cannabinoids, and establishing plant lines having such characteristics.
Abstract: Methods for imaging an analyte in a sample include contacting the biological sample with a binding agent, where the binding agent includes a binding moiety that binds to the analyte and a first nucleotide sequence, contacting the biological sample with a catalytic agent, where the catalytic agent includes a second nucleotide sequence linked to an enzyme, and where the second nucleotide sequence hybridizes to the first nucleotide sequence, contacting the biological sample with a localization agent, where the localization agent includes a substrate complementary to the enzyme and a third nucleotide sequence linked to the substrate, and contacting the biological sample with a labeling agent, where the labeling agent includes a fourth nucleotide sequence linked to an optical label, where the fourth nucleotide sequence hybridizes to the third nucleotide sequence.
Abstract: Crystalline forms of the compound of Formula (I), which modulates the conversion of AMP to adenosine by 5?-nucleotidase, ecto, and compositions containing the compound and methods for preparing the crystalline forms, are described herein. The use of such crystalline form of Formula (I) and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer and immune-related disorders, that are mediated by 5?-nucleotidase, ecto is also provided.
Type:
Grant
Filed:
April 7, 2023
Date of Patent:
April 22, 2025
Assignee:
Arcus Biosciences, Inc.
Inventors:
Andrew M. K. Pennell, Eric F Connor, Stephen Edmund Gottschling, Jim Dimetrios Colomvakos, Mohammed Asadullah Khan
Abstract: Disclosed are recombinant meganucleases engineered to recognize and cleave recognition sequences present in a mutant RHO P23H allele. The invention further relates to the use of such recombinant meganucleases in methods for treating retinitis pigmentosa, wherein the mutant RHO P23H allele is preferentially targeted, cleaved, and inactivated.
Type:
Application
Filed:
December 19, 2024
Publication date:
April 17, 2025
Applicant:
Precision BioSciences, Inc.
Inventors:
Victor Bartsevich, Derek Jantz, J. Jefferson Smith, Michael G. Nicholson
Abstract: A treatment compound and its use in the prevention and treatment diseases are disclosed. The compound comprises one or more materials selected from an algal biomass/supernatant (including both algae and bacteria), a bacterial biomass, and isolated and purified compound(s) as well as specific active sites or structures on those compounds. The bacteria are selected from the group consisting of Algoriphagus sp., Bosea sp., Brevundimonas sp., Desulfovibrio sp., Microbacterium sp., Sphingomonas sp., and Variovorax sp. The disclosed inventive compound and method of treatment find particular application in the treatment of disease in poultry, particularly in the prevention and treatment of coccidiosis.
Type:
Application
Filed:
December 19, 2024
Publication date:
April 17, 2025
Applicant:
Zivo Bioscience, Inc.
Inventors:
Amy E. Steffek, William P. Pfund, Andrew A. Dahl